Multidrug resistance and prodrug activation for cancer gene therapy of breast cancer

Takuma Fujii, S. Q. Fu, L. H. Yin, T. Nanakorn, Felix Garcia Sanchez, Matt Cooperberg, David Guo, Tao Wang, D. Lin, Giuseppe Pizzorno, Albert Deisseroth

Research output: Contribution to journalArticle

Abstract

Current approaches to the treatment of cancer (radiation and chemotherapy) are limited by the toxicity to normal tissues and the sensitivity of tumor cells to these treatments. The use of gene delivery vector systems for the introduction of genetic elements into normal and neoplastic tissues which code for proteins that protect the normal chemotherapy-sensitive tissues and sensitize the tumor cells to radiation and chemotherapy, may contribute to an overall improvement in the outcome of cancer treatment programs. This chapter will review the clinical trials either completed or about to be initiated which are designed to accomplish these goals.

Original languageEnglish
Pages (from-to)210-212
Number of pages3
JournalBreast Cancer
Volume4
Issue number4
DOIs
Publication statusPublished - 01-12-1997
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Multidrug resistance and prodrug activation for cancer gene therapy of breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Fujii, T., Fu, S. Q., Yin, L. H., Nanakorn, T., Sanchez, F. G., Cooperberg, M., Guo, D., Wang, T., Lin, D., Pizzorno, G., & Deisseroth, A. (1997). Multidrug resistance and prodrug activation for cancer gene therapy of breast cancer. Breast Cancer, 4(4), 210-212. https://doi.org/10.1007/BF02966508